Woon Sim, MD
Adult Medicine · Houston, TXNPI 1730130782
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 282 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations.
Across 282 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$901
- Novo Nordisk$668
- Bayer$427
- AbbVie$411
- Amgen$366
- AstraZeneca$351
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,87699%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 57 | $901 |
| Novo Nordisk | 36 | $668 |
| Bayer | 21 | $427 |
| AbbVie(2 entities) | 27 | $411 |
| Amgen | 22 | $366 |
| AstraZeneca | 22 | $351 |
| GSK | 14 | $305 |
| Lilly USA, LLC | 18 | $303 |
| Otsuka America Pharmaceutical, Inc. | 9 | $213 |
| Sumitomo Pharma America, Inc. | 10 | $165 |
| Boehringer Ingelheim | 9 | $158 |
| Nestle Healthcare Nutrition Inc. | 7 | $131 |
| Idorsia Pharmaceuticals US Inc | 4 | $65 |
| Kowa Pharmaceuticals America, Inc. | 3 | $50 |
| Gilead | 2 | $47 |
| Abbott | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Johnson & Johnson | 2 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Irhythm Technologies, Inc. | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Pfizer | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
| Medtronic | 1 | $11 |
How this compares
$4,904 in reported general payments places this provider in the 85th percentile of 98 adult medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $139,467 |
| ProliaDenosumab | 63 | $110,172 |
| JardianceEmpagliflozin | 65 | $107,940 |
| FarxigaDapagliflozin Propanediol | 76 | $105,920 |
| JanuviaSitagliptin Phosphate | 50 | $83,060 |
| VascepaIcosapent Ethyl | 63 | $53,515 |
| KerendiaFinerenone | 63 | $53,077 |
| GemtesaVibegron | 48 | $50,511 |
| CreonLipase/Protease/Amylase | 22 | $50,147 |
| EliquisApixaban | 25 | $43,548 |
| TradjentaLinagliptin | 30 | $43,383 |
| ZenpepLipase/Protease/Amylase | 14 | $36,028 |
| XareltoRivaroxaban | 30 | $35,560 |
| RybelsusSemaglutide | 12 | $31,693 |
| LinzessLinaclotide | 37 | $30,476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $668 | $171,16085 claims |
| Boehringer IngelheimJardiance, Tradjenta | $158 | $151,32495 claims |
| AmgenProlia | $366 | $110,17263 claims |
| AstraZenecaFarxiga, Symbicort | $351 | $108,93287 claims |
| AbbVieCreon, Linzess | $411 | $80,62359 claims |
| BayerKerendia | $427 | $53,07763 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $165 | $50,51148 claims |
| PfizerEliquis | $15 | $43,54825 claims |
| Aimmune Therapeutics, Inc.Zenpep | $29 | $36,02814 claims |
| Johnson & JohnsonXarelto | $30 | $35,56030 claims |
| GileadVemlidy | $47 | $19,72612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 98 adult medicine providers in Texas.
Other adult medicine in Houston
- Latisha RoweHouston$11K
- Marjon MonfaredHouston$2K
- Khoa CaoHouston$2K
- Afaf ShahHouston$2K
- Elise CookHouston$890
- Michael BuxbaumHouston$378
- Maria Isabel ZapataHouston$317
- Deborah HornBellaire$723K
- Thomas MartensPflugerville$87K
- Sakuntalai SrinanthakumarBeaumont$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.